41

Orient Europharma Co Ltd

4120 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

43.50TWD-1.35 (-3.01%)

Price History

Full chart

Market Stats

Previous Close44.85
Open43.20
Day Range42.70 – 43.95
52-Week Range39.05 – 49.60
Volume28.02K
Market Cap4.00B
P/E (TTM)0.00
Forward P/E14.18
EPS-6.64
Dividend Yield8.68%
Beta0.08
50-Day Avg47.13
200-Day Avg45.94

About

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include weight management, andrology, cardiovascular, respiratory, neurology, cardiovascular, metabolism, obstetrics and gynecology, antibiotic, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplements for liquid nutrition, regular blood lipids, L-arginines, agile movements, and improved sleep qualities under the Nutrifuel brand name. In addition, the company offers dermo and cosmetic products under the Cumlaude Labs, AGLabs, Bio-Oil, and ISISPHARMAs brand names. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trial. Orient EuroPharma Co., Ltd. was incorporated in 1982 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMeng-Lin Tsai
  • Employees0
  • HeadquartersNo. 128, Chengde Rd., Taipei, Taiwan, 112052, Taiwan
  • Websitehttps://www.oepgroup.com

Leadership

  • Meng-Lin TsaiGeneral Manager
  • Pin-Chieh WangFinancial Officer & Accounting Officer
  • Liann LaiDirector of Human Resources & Administrative Division
  • Ming-Hsia HungChief Audit Officer

Financials

Income Statement

Currency: TWD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.91B5.23B5.23B5.51B6.09B5.38B4.77B4.73B4.59B4.39B4.60B
Growth (%)-+6.62%-0.11%+5.43%+10.58%-11.65%-11.45%-0.77%-2.93%-4.37%+4.64%
Cost of Revenue2.74B2.82B2.76B2.93B3.28B2.96B2.62B2.70B2.44B2.33B2.36B
Gross Profit2.17B2.41B2.47B2.58B2.81B2.42B2.15B2.03B2.15B2.07B2.24B
Gross Margin44.14%46.12%47.22%46.83%46.19%44.99%45.12%42.96%46.76%47.05%48.69%
Operating Expense1.90B1.96B2.03B2.22B2.48B2.30B2.25B2.18B2.08B2.05B2.54B
Operating Income263.54M450.85M435.42M357.19M331.06M117.36M-98.15M-149.93M72.14M13.32M-298.82M
Operating Margin5.37%8.62%8.33%6.48%5.43%2.18%-2.06%-3.17%1.57%0.30%-6.50%
EBITDA--645.71M490.20M572.23M476.93M313.89M-64.29M578.61M183.90M-1.18M
EBITDA Margin--12.35%8.90%9.39%8.86%6.58%-1.36%12.60%4.19%-0.03%
Net Income223.16M469.61M458.73M246.74M247.66M199.30M120.17M-310.80M143.94M-283.93M-567.39M
Net Income Margin4.55%8.98%8.78%4.48%4.06%3.70%2.52%-6.57%3.13%-6.47%-12.35%
R&D424.57M363.38M378.76M389.47M394.60M366.56M331.09M259.84M206.59M242.22M558.41M
R&D as % of Total Revenue8.65%6.95%7.25%7.07%6.48%6.81%6.95%5.49%4.50%5.52%12.15%
Interest Expense00016.46M24.92M30.23M38.04M69.53M106.10M107.23M74.06M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.30%0.41%0.56%0.80%1.47%2.31%2.44%1.61%

Balance Sheet

Currency: TWD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets5.47B6.49B6.65B7.24B7.87B8.16B9.40B10.43B10.81B11.57B12.21B
Total Liabilities2.09B2.57B2.56B3.10B4.06B4.25B5.95B6.99B6.65B5.75B4.85B
Total Equity2.89B3.14B3.27B3.28B3.19B3.21B2.94B2.93B3.51B5.16B6.29B
Cash1.04B1.34B1.30B1.75B1.75B2.12B1.96B1.80B1.74B1.44B1.95B
Net Debt----156.24M24.33M1.77B2.73B2.65B2.40B986.00M

Cash Flow

Currency: TWD2008-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-643.97M111.24M601.08M231.31M227.37M608.55M77.65M-218.75M64.67M-121.11M-292.21M
Investing Cash Flow--515.63M-383.50M-255.95M-196.56M-199.95M-367.59M-1.50B-611.56M---
Financing Cash Flow-150.64M613.44M-221.89M378.14M63.21M222.51M1.36B428.31M---
Capital Expenditure0229.54M224.81M367.66M201.61M124.98M232.78M1.56B639.16M100.70M100.20M188.64M
Free Cash Flow---364.28M26.88M48.68M373.43M-1.49B-859.84M-36.03M-221.31M-480.85M
Dividends Paid-138.79M170.76M156.15M216.87M156.15M156.15M130.12M73.73M15.58M100.96M101.04M
FCF to OCF---60.60%11.62%21.41%61.36%-1919.17%393.07%-55.71%182.74%164.56%
Dividend Paid to FCF---42.86%806.80%320.78%41.81%-8.73%-8.58%-43.24%-45.62%-21.01%

Earnings

Report DateOct 29, 2007Apr 30, 2009Aug 27, 2009May 15, 2019Aug 14, 2019Nov 14, 2019Aug 9, 2020Nov 10, 2020
EPS Estimate0.630.750.760.940.631.140.630.57
EPS Actual0.600.890.701.500.620.361.48-0.15
Surprise-4.76%18.67%-7.89%59.57%-1.59%-68.42%134.92%-126.32%
TimingPre-marketPre-marketPre-marketPre-marketPre-market-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap4.00B
Enterprise Value5.98B
Trailing P/E0.00
Forward P/E14.18
Price / Sales0.86
Price / Book0.76
EPS-6.64
Book Value60.28
Revenue (TTM)4.65B
Gross Profit (TTM)2.27B
EBITDA-192.10M
Profit Margin-12.38%
Operating Margin-10.54%
Return on Equity-7.15%
Return on Assets-1.82%
Shares Outstanding86.75M
Shares Float31.45M
Beta0.08
Dividend Yield8.68%
Dividend Rate4.00
Payout Ratio0.00%

Dividends

20261×
4.00Jul 20, 2026
20251×
1.00Jul 7, 2025
20241×
1.00Jul 19, 2024
20221×
0.85Jul 18, 2022
20211×
1.50Sep 14, 2021
20201×
1.80Jul 7, 2020
20191×
1.80Jul 11, 2019
20181×
2.50Jul 10, 2018
20171×
1.80Jun 23, 2017
20161×
1.80Jun 22, 2016
20151×
1.60Jul 16, 2015
20141×
1.67Jul 10, 2014
20131×
1.90Jul 8, 2013
20121×
1.20Jun 29, 2012
20111×
0.65Jun 24, 2011
20101×
0.37Jul 28, 2010
20091×
0.36Aug 13, 2009
20081×
0.37Jul 29, 2008

Stock Splits

  • Jul 28, 20101160:1000
  • Aug 13, 20091.1421:1
  • Jul 29, 20081.0999:1